Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Sumitra, Thongprasert"'
Autor:
Malvika Vyas, Melanie Bertram, Jean-Yves Douillard, Alexandru Eniu, Nathan I Cherny, Sumitra Thongprasert, Gracemarie Bricalli, Dario Trapani
Publikováno v:
ESMO Open, Vol 4, Iss 4 (2019)
This review article is an overview of the session at the European Society for Medical Oncology (ESMO) Asia 2018 Congress entitled: 'Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?'. The article provides an ov
Externí odkaz:
https://doaj.org/article/8366ca719a0f4a6bad2020e5555815f4
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Supplementary Figure 1. (A) PFS in the cfDNA mut+ subgroup (B) OS in the cfDNA mut+ subgroup (C) PFS in the cfDNA mut+ subgroup (patients with no tissue result) (D) OS in the cfDNA mut+ subgroup (patients with no tissue result) (E) PFS in the cfDNA m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99267496a9f0d581dbea95dfc1b10c8e
https://doi.org/10.1158/1078-0432.22459443.v1
https://doi.org/10.1158/1078-0432.22459443.v1
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Supplementary Tables 1-4. Supplementary Table 1. Concordance, sensitivity, specificity, positive and negative predictive values of tissue and cfDNA tests (n=238) by EGFR mutation type Supplementary Table 2: EGFR mutation type Supplementary Table 3: E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4987cacd97c4d34db3f643a69c08b68
https://doi.org/10.1158/1078-0432.22459440
https://doi.org/10.1158/1078-0432.22459440
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study.Experimental Design: Patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd7c00c885259dc1fc67b73bb4dbefa
https://doi.org/10.1158/1078-0432.c.6524220
https://doi.org/10.1158/1078-0432.c.6524220
Autor:
Chitchamai Siangproh, Kritsana Suthisri, Nirush Lertprasertsuke, Sumitra Thongprasert, Christina Gonzales, Lertlakana Bhoopat, Sawang Saenghirunvattana
Publikováno v:
The Bangkok Medical Journal. 14:5-9
RATIONALE: Non-small cell lung cancer (NSCLC) remains the leading cause ofcancer-related deaths among Asian population. Liquid biopsy is a new technology thatprovides information on tumor gene profiling through examination of cell-free DNA(CfDNA) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7c5805df6f8fe435abd551b14e05dfe
https://doi.org/10.31524/bkkmedj.2018.02.002
https://doi.org/10.31524/bkkmedj.2018.02.002
Autor:
Eun Kyung Cho, Keunchil Park, Mauro Orlando, Maximino Bello, Tarun Puri, H. Depenbrock, Sumitra Thongprasert, Victoria Soldatenkova, Eun-Kee Song, Myung-Ju Ahn
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40fb4ef0b3c1290ae073b50f46a117b5
https://doi.org/10.4143/crt.2016.423
https://doi.org/10.4143/crt.2016.423
Autor:
Sumitra Thongprasert, Mercedes Liliana Dalurzo, Nirush Lertprasertsuke, Bojan Zaric, Ahmed Rabea, Fred R. Hirsch, Marileila Varella-Garcia
Publikováno v:
American Society of Clinical Oncology Educational Book. :403-408
There have been many important advances in personalized therapy for patients with lung cancer, particularly for those with advanced disease. Molecular testing is crucial for implementation of personalized therapy. Although the United States and many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680810966c6b9d8e9e0d567cd6ce2ec2
https://doi.org/10.1200/edbk_175243
https://doi.org/10.1200/edbk_175243
Autor:
Yuichiro Ohe, Masahiro Fukuoka, Yukito Ichinose, Busayamas Chewaskulyong, Nagahiro Saijo, Tony Mok, Sumitra Thongprasert, Benjamin Margono, Baohui Han, Yuri Rukazenkov, Yi-Long Wu, Helen Young, Vincent Haddad, James Chih-Hsin Yang, Patrapim Sunpaweravong, Jin-Ji Yang
Publikováno v:
Lung Cancer. 104:119-125
Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73516d8c4bc8ad22f3b45c019de83fde
Autor:
Jasmin Reyes-Igama, Agnieszka Cseh, Sumitra Thongprasert, Sheethal Suresh, Piotr Serwatowski, Sarayut Lucien Geater, Michael Schenker, Virote Sriuranpong, Dragana Jovanovic, Aurelia Alexandru, A. Abdelaziz, Rabab Gaafar, Dana Clement
Publikováno v:
Lung Cancer Management
Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive ( EGFRm+) non-small-cell lung cancer (NSCLC) following chemotherapy. Patients & methods: In this open-label, single-arm Pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e09f8b4c04de34329f7a3134d915339
http://europepmc.org/articles/PMC6891940
http://europepmc.org/articles/PMC6891940
Autor:
Sumitra Thongprasert, Frederic Lehmann, Pan-Chyr Yang, Jamila Louahed, Aung Myo, Jung Shin Lee, Vincent Brichard, Ross A. Soo, Thierry Coche, Olivier Gruselle
Publikováno v:
Lung Cancer. 101:137-144
Introduction Treatment of non-small cell lung cancer (NSCLC) is an important and often unmet medical need regardless of the disease stage at the time of first diagnosis. Antigen-specific immunotherapy may be a feasible therapeutic option if tumor ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ebeaa560b4676b13b38a484038c9ac